Leerink

The consensus estimates for Gilead Sciences, Inc. (NASDAQ: GILD) appear overly conservative, especially given the prospects of remdesivir and products from the company’s recent collaboration with Arcus Biosciences Inc (NYSE: RCUS), according to Leerink. The Gilead Sciences Analyst Geoffrey...

Biogen Inc (NASDAQ: BIIB) to acquire gene therapy company Nightstar Therapeutics PLC (NASDAQ: NITE). Roche Holdings AG Basel ADR (OTC: RHHBY) agrees to buy Spark Therapeutics Inc (NASDAQ: ONCE). Sarepta Therapeutics Inc (NASDAQ: SRPT) exercises option to buy Myonexus Therapeutics for $165...

With more and more genetic medicine companies going commercial, Leerink turned its attention to the sector this week.  The Analyst Leerink’s Mani Foroohar initiated coverage of 10 genetic medicine companies with the following ratings and price targets: bluebird bio (NASDAQ:...

Leerink is taking a bullish stance on GW Pharmaceuticals PLC (ADR) (NASDAQ: GWPH), with a thesis centering around the company's lead drug Epidiolex; the drug Sativex; GW's involvement in the epilepsy market and its cannabinoid science platform. The Analyst Leerink's Marc Goodman...

TEVA Pharmaceutical Industries (NASDAQ: TEVA)'s fundamentals have substantially improved over the last few months, giving the stock a more balanced risk-reward profile, according to Leerink.  The Analyst Leerink analyst Ami Fadia upgraded TEVA Pharmaceutical from Underperform to Market...

Leerink sees potential in Translate Bio Inc (NASDAQ: TBIO) mRNA-based candidate for cystic fibrosis patients with Class I mutations. The Analyst Leerink's Geoffrey Porges initiated coverage of Translate Bio with an Outperform rating and $24 price target.  The Thesis Around 12...

A U.S. District Court approved AT&T Inc. (NYSE: T)'s purchase of Time Warner Inc (NYSE: TWX) Tuesday and advised the Justice Department not to seek a stay of the ruling. The results were celebrated by stocks involved in and distantly peripheral to the case — and left analysts...

The Street is making up its mind on May’s market newbies, and ASLAN PHARMACEUTICALS ADR REP 5 ORD (NASDAQ: ASLN) received its judgment Wednesday. Two analysts issued Buy ratings and one a Market Perform. Here are the details on the more bearish thesis.  The Rating Leerink analyst...

Hologic, Inc. (NASDAQ: HOLX) reported fiscal second-quarter results that prompted Leerink to drop its bullish stance on the women's health-focused medical technology company.  The Analyst Leerink's Richard Newitter downgraded Hologic's stock rating from Outperform to Market...

Mylan NV (NASDAQ: MYL)’s had a rough three years, but one analyst left the pharma company's investor day with fresh optimism. The Rating Leerink analyst Ami Fadia upgraded Mylan from Market Perform to Outperform and maintained a $52 price target. The Thesis By Leerink’s...

The CNBC Healthy Returns Conference recently came to an end, and Leerink analyst Ana Gupte summarized the key takeaways from the event in a note on Thursday. Here’s what investors need to know: According to venture capital and private equity investors, one of the largest investment...

ARMO Biosciences Inc (NASDAQ: ARMO)'s lead product candidate AM0010 is a drug for the treatment of pancreatic ductal adenocarcinoma recently showed "promising" data that's supportive of a potentially large commercial opportunity, according to Leerink. The Analyst Leerink's...

It’s earnings season, and a steady stream of financial figures are separating the flawed from the flourishing in the pharmaceutical sector.  The Ratings Leerink reiterated Outperform ratings on the following stocks: Zogenix, Inc. (NASDAQ: ZGNX), with a price target increase from $...

AbbVie Inc (NYSE: ABBV) shares ran up about 14 percent last Friday following the release of fiscal fourth-quarter results, where it revealed expectations for higher earnings and a lower tax rate in 2018. The Analyst Leerink analyst Geoffrey Porges downgraded shares of AbbVie from...